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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S174Conclusions: Forty percent of eligible patients agreed to participate in the
study. This number is similar to earlier surgical placebo controlled trials
from other countries. A high proportion of these patients were later
excluded due to the absence of a medial meniscus lesion on MRI, con-
ﬁrming a poor correlation between clinical signs and MRI ﬁndings.
This study conﬁrms the feasibility of recruiting patients for surgical
placebo controlled trials but highlights the challenges of recruiting to
surgical RCT's. Future studies should emphasize the oral information given
at the initial screening and the importance of the study for future patients.
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PREVALENCE OF CLINICAL DIGITAL OSTEOARTHRITIS (HEBERDEN AND
BOUCHARD NODES) IN A SELECTED POPULATION OF PATIENTS WITH
SEVERE OBESITY: A PROSPECTIVE STUDY
N. Thelier-Deloison 1, X. Chevalier 1, J.-M. Oppert 2, C. Poitou-Bernert 2. 1AP-
HP Hôpital Henri Mondor, Creteil, France; 2AP-HP Hôpital La Pitié Salpêtrière,
Paris, France
Purpose: Hand osteoarthritis (HOA) is the most frequent form of osteo-
arthritis (60%). The main risk factors of HOA are: age above 40, women,
obesity, heredity and work. A recent meta-analysis seems to indicate that
obesity (through the systemic release of pro inﬂammatory mediators such
adipokines) is a risk factor of HOA (OR¼1.9). However, results of studies
analyzing obesity as a risk factor of HOA are mixed and focused on
radiological HOA. If obesity is a substantial risk factor of HOA, we
hypothesize that patients with severe obesity may present a high preva-
lence of this disease. The aim of the present was to study the prevalence of
HOA which is deﬁned as Heberden nodes in a prospective observational
study in a population of patients with severe obesity (BMI>35 kg/m2)
followed in specialized clinical nutrition department at a university
hospital in Paris, France (Pitié Salpêtrière).
Methods: A senior rheumatologist collected demographic information
(personal and familial histories, current treatment, hand pain), question-
naires of hand disability (DREISER and Cochin) and performed a complete
detailed physical examination. Heberden and Bouchard nodes were diag-
nosed by a physical examination of hand joints and knee OAwas conﬁrmed
by previous medical history. We studied the association (Fisher's exact
test) between knee and hand osteoarthritis to explore if obesity is a risk
factor of multiple osteoarthritis.
Results:We studied 112 patients: 65% of women, average age 47.1 years and
averageBMI45.9kg/m2(30.8-69.1).We foundahighproportionofHeberden
nodes (16.1%), noteworthy particularly in the second and third ﬁngers and
a prevalence of Bouchard nodes of 1.8%. A third of patientswith clinical hand
osteoarthritis had hand pain and did not report hand disability. Knee oste-
oarthritis was reported in 23.2% of subjects. We found a signiﬁcant link
between knee and hand osteoarthritis (p¼0.006). Multivariate analysis
(taking into account age, sex, BMI, diabetes mellitus, hypertension and
cholesterol serum level) showed that agewas a signiﬁcant risk factor of HOA
[OR¼1.11 (IC 95%: 1.04-1.17)] and knee osteoarthritis [OR¼1.08 (IC 95%: 1.02-
1.15)]. Univariate analysis showed that patients with knee osteoarthritis
more often had diabetes mellitus (57.6% vs 26.7%, p¼0.003), hypertension
(73.1% vs 32.6%, p¼0.006) and dyslipidemia (42.3% vs 4.7%, p¼5.10-5).
Conclusions: In comparison with the known prevalence of clinical HOA in
other series of patients aged over 55 years (4% to 14.9%), we found a high
prevalence of Heberden nodes in this selected population of relatively
young patients (mean age 47 years) with severe obesity, suggesting
a systemic participation of adipose tissue. Moreover disturbances that are
part of the metabolic syndrome could participate in the development of
knee osteoarthritis which is otherwise linked to HOA.
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NON-INVASIVE ELECTROMAGNETIC FIELD THERAPY PRODUCES RAPID
AND SUBSTANTIAL PAIN REDUCTION IN EARLY KNEE
OSTEOARTHRITIS: A RANDOMIZED DOUBLE-BLIND PILOT STUDY.
F. Nelson 1, R. Zvirbulis 1, A.A. Pilla 2. 1Henry Ford Hosp., Detroit, MI;
2Columbia Univ., New York City, NY, USA
Purpose: Pulsed electromagnetic ﬁelds (PEMF) have been employed for
treatment of knee Osteoarthritis (OA) with varied success. PEMF signalshave been shown to modulate CaM-dependent signaling pathways that
orchestrate the release of cytokines and growth factors in cellular
responses to injury. This study was designed to determine if PEMF
conﬁgured to modulate CaM/NO/cGMP signaling would reduce pain in
early knee OA.
Methods: This IRB approved double-blind, placebo-controlled, random-
ized pilot study used VAS pain scores on a 0-10 cm scale with respect to
baseline as an outcome measure for each cohort. Patient selection was
knee pain for at least 3 months with an imaging study conﬁrming cartilage
loss, an initial VAS score  4, and at least 2 hours of daily standing activity
in a physical occupation. Patients with rheumatoid arthritis, gout, preg-
nancy, cortisone injections, surgery, or viscosupplementation were
excluded. The PEMF signal consisted of a 7 msec burst of 6.8 MHz sinu-
soidal waves repeating at 1burst/sec delivering a peak induced electric
ﬁeld of 34  8 V/m in the knee. The light-weight portable battery operated
device was used 15minutes twice daily, andcould be easily placed over the
knee with clothing. Blinding was maintained because this PEMF can only
be detected with specialized equipment. Un-blinding occurred after all
data was collected. Patients self-reported maximum daily VAS pain scores
on an unmarked horizontal 10 cm line (0 ¼ no pain, 10 ¼ worst possible
pain) at baseline (day 0), daily for the ﬁrst 14 days and from day 29 to day
42. Results were analyzed using the Student's t-test or one way repeated
measures ANOVA with Holm-Sidek post hoc analysis, as appropriate.
Signiﬁcance was P  0.05. Data is displayed  SEM.
Results: Therewere no adverse effects and the devices werewell tolerated.
There were no signiﬁcant baseline differences in mean age, body mass
index (BMI), or Kellgren-Lawrence (K-L) radiographic scores, between
active and sham cohorts. Thirty four patients started treatment. Of these,
19 (14F, 5M) were shams, and 15 (10F, 5M) were actives. All enrolled
patients received PEMF treatment to day 14. Thereafter, 3 active and 7
sham patients dropped out of the study by day 42, citing lack of perceived
beneﬁt as the reason, conﬁrmed by VAS scores. The PEMF signal caused
50%  11% decrease in mean maximum VAS vs mean baseline VAS for the
treated group on day 1, persisting to day 42 (P < 0.001). There was no
signiﬁcant decrease in meanmaximum VAS in the sham group (P¼ 0.227).
The overall decrease in VAS scores from baselinewas 2.7 0.57 (P< 0.001)
for the active group vs 1.5 0.41 (P¼ 0.168) for the sham group. There was
no signiﬁcant difference in mean start VAS between active and sham
groups.
Conclusions: This non-thermal, non-invasive PEMF, when conﬁgured to
dose CaM/NO/cGMP signaling, has a signiﬁcant and rapid impact on pain
from early knee OA. The PEMF effect on pain is consistent with the known
rapid effect of NO signaling on reduction of effusion. The intervention is
novel because it is non-pharmacological, and the patient population did
not have end stage OA and was required to be on their feet at least two
hours a day.Ă
